Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a multicenter, randomized, controlled, open-label clinical trial testing the use of ozone auto-hemotherapy in hospitalized patients with Covid-19 pneumonia. Eligible patients will be randomly assigned to receive either ozone auto-hemotherapy plus standard treatment, or standard treatment alone. Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days. Standard treatment will be the one used in each hospital participating in the trial. All analyses will be done according to the intention-to-treat principle
Description: Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)
Measure: Rate of patients achieving improvement in clinical condition at day 14 after recruitment Time: 14 daysDescription: mortality
Measure: Mortality at day 28 Time: 28 daysDescription: Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)
Measure: Rate of patients achieving improvement in clinical condition at day 28 after recruitment Time: 28 daysDescription: Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)
Measure: Rate of patients achieving improvement in clinical condition at day 7 after recruitment Time: 7 daysDescription: Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)
Measure: Time to clinical improvement or hospital discharge Time: 28 daysDescription: Ventilator-free days from last extubation day until day 28 after recruitment
Measure: Number of ventilator-free days at 28 days Time: 28 daysDescription: Days hospitalized
Measure: Hospital length of stay Time: 28 daysDescription: Number of days until a 2-fold decrease in ferritin (ng/mL)
Measure: Time to a 2-fold decrease in ferritin Time: 14 daysDescription: Number of days until a 2-fold decrease in C-Protein Reactive (mg/L)
Measure: Time to a 2-fold decrease in C-protein reactive Time: 14 daysDescription: Number of days until a 2-fold decrease in Dimer-D (ng/mL)
Measure: Time to a 2-fold decrease in Dimer-D Time: 14 daysDescription: Number of days until a 2-fold decrease in Lactate Dehydrogenase (U/L)
Measure: Time to a 2-fold decrease in Lactate Dehydrogenase Time: 14 daysDescription: Number of days until a 2-fold decrease in Neutrophils to Lymphocytes ratio
Measure: Time to a 2-fold decrease in Neutrophils to Lymphocytes ratio Time: 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports